MCID: PLY187
MIFTS: 37

Polyarticular Juvenile Idiopathic Arthritis

Categories: Bone diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Polyarticular Juvenile Idiopathic Arthritis

MalaCards integrated aliases for Polyarticular Juvenile Idiopathic Arthritis:

Name: Polyarticular Juvenile Idiopathic Arthritis 58 17
Juvenile Polyarthritis 58 32
Juvenile Polyarticular Arthritis 58
Polyarticular Jia 58

Classifications:

Orphanet: 58  
Rare respiratory diseases
Rare systemic and rhumatological diseases


External Ids:

ICD10 32 M08.3
UMLS via Orphanet 72 C0409667
Orphanet 58 ORPHA404580

Summaries for Polyarticular Juvenile Idiopathic Arthritis

MalaCards based summary : Polyarticular Juvenile Idiopathic Arthritis, also known as juvenile polyarthritis, is related to pericarditis and rheumatoid factor-positive polyarticular juvenile idiopathic arthritis. An important gene associated with Polyarticular Juvenile Idiopathic Arthritis is BTK (Bruton Tyrosine Kinase), and among its related pathways/superpathways are IL-2 Pathway and Th17 cell differentiation. The drugs Hydroxychloroquine and Methylprednisolone have been mentioned in the context of this disorder. Affiliated tissues include bone, liver and t cells.

Related Diseases for Polyarticular Juvenile Idiopathic Arthritis

Diseases in the Polyarticular Juvenile Idiopathic Arthritis family:

Polyarticular Onset Juvenile Idiopathic Arthritis

Diseases related to Polyarticular Juvenile Idiopathic Arthritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 176)
# Related Disease Score Top Affiliating Genes
1 pericarditis 29.4 TNF IFNG
2 rheumatoid factor-positive polyarticular juvenile idiopathic arthritis 12.9
3 arteritis, familial granulomatous, with juvenile polyarthritis 12.4
4 juvenile rheumatoid arthritis 12.1
5 multicentric carpotarsal osteolysis syndrome 11.6
6 polyarticular onset juvenile idiopathic arthritis 11.5
7 arthritis 10.6
8 rheumatoid factor-negative juvenile idiopathic arthritis 10.5
9 rheumatoid factor-negative juvenile idiopathic arthritis without anti-nuclear antibodies 10.5
10 rheumatoid factor-negative juvenile idiopathic arthritis with anti-nuclear antibodies 10.5
11 uveitis 10.4
12 rheumatic disease 10.4
13 autoimmune disease 10.3
14 agammaglobulinemia, x-linked 10.3
15 enthesopathy 10.3
16 agammaglobulinemia 10.3
17 macrophage activation syndrome 10.3
18 transient hypogammaglobulinemia 10.2 TNF BTK
19 aortic valve insufficiency 10.2
20 enthesitis-related juvenile idiopathic arthritis 10.2
21 pyoderma 10.1 TNF BTK
22 torticollis 10.1
23 multicentric osteolysis, nodulosis, and arthropathy 10.1
24 non-alcoholic fatty liver disease 10.1
25 nasopharyngitis 10.1
26 ventricular septal defect 10.1
27 heart septal defect 10.1
28 ankylosis 10.1
29 arthropathy 10.1
30 pustulosis of palm and sole 10.1
31 fibromyalgia 10.1
32 double outlet right ventricle 10.1
33 crohn's disease 10.1
34 psoriasis 10.1
35 iridocyclitis 10.1
36 fatty liver disease 10.1
37 47,xyy 10.1
38 spondylarthropathy 10.1
39 systemic onset juvenile idiopathic arthritis 10.1
40 oligoarticular juvenile idiopathic arthritis 10.1
41 rheumatoid arthritis 10.0
42 cd40 ligand deficiency 9.9 IFNG BTK
43 panniculitis 9.9 IFNG BTK
44 staphylococcal toxic shock syndrome 9.9 TNF IFNG
45 autoimmune myocarditis 9.9 TNF IFNG
46 spotted fever 9.9 TNF IFNG
47 spotted fever rickettsiosis 9.9 TNF IFNG
48 chronic beryllium disease 9.9 TNF IFNG
49 soft tissue sarcoma 9.9 TNF IFNG
50 gastrointestinal tuberculosis 9.9 TNF IFNG

Graphical network of the top 20 diseases related to Polyarticular Juvenile Idiopathic Arthritis:



Diseases related to Polyarticular Juvenile Idiopathic Arthritis

Symptoms & Phenotypes for Polyarticular Juvenile Idiopathic Arthritis

Drugs & Therapeutics for Polyarticular Juvenile Idiopathic Arthritis

Drugs for Polyarticular Juvenile Idiopathic Arthritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 42)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydroxychloroquine Approved Phase 3 118-42-3 3652
2
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
3
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
4
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
5 Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
6
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
7
Naltrexone Approved, Investigational, Vet_approved Phase 3 16590-41-3 5360515
8
Infliximab Approved Phase 3 170277-31-3
9
Ethanol Approved Phase 3 64-17-5 702
10
Sulfasalazine Approved Phase 3 599-79-1 5353980 5359476
11
Etanercept Approved, Investigational Phase 3 185243-69-0
12
Abatacept Approved Phase 3 332348-12-6 10237
13
tannic acid Approved Phase 3 1401-55-4
14
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
15
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
16
leucovorin Approved Phase 3 58-05-9 6006 143
17
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
18
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
19 Methylprednisolone Acetate Phase 3
20 Narcotics Phase 3
21 Narcotic Antagonists Phase 3
22 Pharmaceutical Solutions Phase 3
23 Gastrointestinal Agents Phase 3
24 Anti-Inflammatory Agents, Non-Steroidal Phase 3
25 Analgesics, Non-Narcotic Phase 3
26 Immunosuppressive Agents Phase 3
27 Analgesics Phase 3
28 Rheumatoid Factor Phase 3
29 Folic Acid Antagonists Phase 3
30 Vitamin B Complex Phase 3
31 Vitamin B9 Phase 3
32 Dermatologic Agents Phase 3
33 Folate Phase 3
34 Antimetabolites Phase 3
35 Antibodies, Monoclonal Phase 3
36 Immunoglobulins Phase 3
37 Antibodies Phase 3
38
Tyrosine Approved, Investigational, Nutraceutical Phase 1 60-18-4 6057
39
Adalimumab Approved 331731-18-1 16219006
40 Anti-Inflammatory Agents
41 Immunologic Factors
42 Antirheumatic Agents

Interventional clinical trials:

(show all 24)
# Name Status NCT ID Phase Drugs
1 Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA Completed NCT00792233 Phase 4
2 Comparison of Anti-TNF Therapy Plus Methotrexate, Combination Therapy of DMARDs, and Methotrexate Alone in Very Early Polyarticular Juvenile Idiopathic Arthritis. A National Randomized Multicenter Clinical Trial. Completed NCT01015547 Phase 3 Infliximab plus methotrexate;Combination of DMARDs;Methotrexate alone
3 An Open-label, Extension, Phase III Study to Evaluate the Long-term Safety, Efficacy and PK of MRA in Patients With pJIA Who Participated in Study MRA318JP Completed NCT00144625 Phase 3 MRA(Tocilizumab)
4 Compassionate Use Study of Adalimumab in Children 2 to < 4 Years Old or Age 4 and Above Weighing Less Than 15 kg With Active Juvenile Idiopathic Arthritis (JIA) Completed NCT00775437 Phase 3 Adalimumab
5 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Efficacy, and Pharmacokinetics of the Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis Completed NCT00048542 Phase 3 OLE BSA Adalimumab +/- MTX;OLE FD Adalimumab +/- MTX
6 Treatment Tapering in Oligoarticular or Rheumatoid Factor Negative Polyarticular Juvenile Idiopathic Arthritis With Inactive Disease on Biologic Therapy Recruiting NCT02840175 Phase 3 etanercept;adalimumab;Abatacept;Tocilizumab
7 A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JIA) Recruiting NCT03773978 Phase 3 Baricitinib;Placebo
8 A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA) Recruiting NCT03773965 Phase 3 Baricitinib
9 A Randomized, Open Label, Multi-Center, Phase 3 Efficacy Study of Sub-Q Abatacept in Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA) Recruiting NCT03841357 Phase 3 Abatacept Injection
10 A Phase 3 Multi-center, Open-Label Study to Evaluate Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Active, not recruiting NCT01844518 Phase 3
11 A Multicenter, Double-Blind, Randomized-Withdrawal Trial of Subcutaneous Golimumab, a Humanized Anti-TNFa Antibody, in Subjects With Active Polyarticular Juvenile Idiopathic Arthritis (JIA) Despite Standard Therapy Terminated NCT01230827 Phase 3 CNTO 148 (Golimumab);Placebo;Methotrexate
12 A Multicenter, Open Label, Dose Finding Study to Evaluate Efficacy and Safety of Givinostat Administered in Two Different Doses in Patients With Poly JIA Not Adequately Responding to the Standard Treatment. Terminated NCT01261624 Phase 2 Givinostat
13 A Randomized, Double Blind, Placebo Controlled Clinical Trial to Evaluate the Efficacy of Abatacept Costimulatory Blockade in the Treatment of Alopecia Totalis/Universalis Withdrawn NCT01314495 Phase 2 Abatacept;Inactive infusion
14 A Phase Ib, Open-Label, Multicenter Study to Investigate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab Following Subcutaneous Administration to Patients With Polyarticular Juvenile Idiopathic Arthritis Completed NCT01904279 Phase 1 Tocilizumab
15 Phase I Study of Itacitinib in Combination With Tocilizumab for the Treatment of Steroid Refractory Acute Graft Versus Host Disease Not yet recruiting NCT04070781 Phase 1 Itacitinib;Tocilizumab
16 Enbrel-JIA Use Results Survey [All-Case Surveillance] Completed NCT01145352 Etanercept (genetical recombination)
17 Post-Marketing Surveillance of Humira Injection in Korean JIA Patients Under the New-Drug Re-examination Completed NCT02141984
18 Patient Centered Adaptive Treatment Strategies for Juvenile Idiopathic Arthritis Using Bayesian Causal Inference Completed NCT02524340
19 Determination of the Effective Individual Dose of Etanercept in Patients Treated for Juvenile Idiopathic Arthritis Completed NCT02030613
20 Start Time Optimization of Biologics in Polyarticular JIA Completed NCT02593006
21 A Long-term, Multi-center, Longitudinal Post-marketing, Observational Study to Assess Long Term Safety and Effectiveness of HUMIRA® (Adalimumab) in Children With Moderately to Severely Active Polyarticular or Polyarticular-course Juvenile Idiopathic Arthritis (JIA) - STRIVE Active, not recruiting NCT00783510 Methotrexate
22 Golimumab in Juvenile Idiopathic Arthritis-associated Uveitis Failing Adalimumab Active, not recruiting NCT04200833 Golimumab
23 Emergency IND for Provision of Tocilizumab No longer available NCT00862758 Tocilizumab
24 An Open-Label Extension of the Dose Finding Study (DSC/08/2357/36) in Patients With Polyarticular Course Juvenile Idiopathic Arthritis (Poly JIA) JIA Terminated NCT01557452 Givinostat

Search NIH Clinical Center for Polyarticular Juvenile Idiopathic Arthritis

Genetic Tests for Polyarticular Juvenile Idiopathic Arthritis

Anatomical Context for Polyarticular Juvenile Idiopathic Arthritis

MalaCards organs/tissues related to Polyarticular Juvenile Idiopathic Arthritis:

40
Bone, Liver, T Cells, Whole Blood, B Cells, Neutrophil, Thymus

Publications for Polyarticular Juvenile Idiopathic Arthritis

Articles related to Polyarticular Juvenile Idiopathic Arthritis:

(show top 50) (show all 188)
# Title Authors PMID Year
1
Outcome Monitoring and Clinical Decision Support in Polyarticular Juvenile Idiopathic Arthritis. 61
31308202 2020
2
Biologic Therapies in Polyarticular Juvenile Idiopathic Arthritis. Comparison of Long-Term Safety Data from the German BIKER Registry. 61
31943968 2020
3
Arthritis in children with LRBA deficiency - case report and literature review. 61
31847838 2019
4
Health-related quality of life during early aggressive treatment in patients with polyarticular juvenile idiopathic arthritis: results from randomized controlled trial. 61
31842940 2019
5
Physical Fitness in Patients With Oligoarticular and Polyarticular Juvenile Idiopathic Arthritis Diagnosed in the Era of Biologics: A Controlled Cross-Sectional Study. 61
30474929 2019
6
Infliximab therapy and outcomes in patients with polyarticular juvenile idiopathic arthritis: a single-center study in China. 61
31612428 2019
7
Canakinumab in Children with Familial Mediterranean Fever: A Single-Center, Retrospective Analysis. 61
31463794 2019
8
[Biologics in the treatment of juvenile idiopathic arthritis : A comparison of mono- and combination therapy with synthetic DMARDs]. 61
31087133 2019
9
Efficacy and safety of tocilizumab in a real-life observational cohort of patients with polyarticular juvenile idiopathic arthritis. 61
31359057 2019
10
Expanding the spectrum of A20 haploinsufficiency in two Chinese families: cases report. 61
31299923 2019
11
Comparison of Adults With Polyarticular Juvenile Idiopathic Arthritis to Adults With Rheumatoid Arthritis: A Cross-sectional Analysis of Clinical Features and Medication Use. 61
29781829 2019
12
Population Pharmacokinetics and Exposure-Response Modeling Analyses of Golimumab in Children With Moderately to Severely Active Ulcerative Colitis. 61
30536638 2019
13
Biallelic loss-of-function LACC1/FAMIN Mutations Presenting as Rheumatoid Factor-Negative Polyarticular Juvenile Idiopathic Arthritis. 61
30872671 2019
14
Slow speed resistance exercise training in children with polyarticular juvenile idiopathic arthritis. 61
31191051 2019
15
PAIN PERCEPTION AND PAIN COPING MECHANISMS IN CHILDREN AND ADOLESCENTS WITH JUVENILE FIBROMYALGIA AND POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS. 61
29898009 2019
16
Height and sexual maturation in girls with juvenile idiopathic arthritis. 61
30339783 2018
17
Physical activity in patients with oligo- and polyarticular juvenile idiopathic arthritis diagnosed in the era of biologics: a controlled cross-sectional study. 61
30333025 2018
18
SB5: An Adalimumab Biosimilar. 61
30251234 2018
19
Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn's Disease. 61
30054164 2018
20
Early prediction for over two years efficacy of the first biologic agent for polyarticular juvenile idiopathic arthritis: A multi-institutional study in Japan. 61
29293033 2018
21
Identification of enhanced IFN-γ signaling in polyarticular juvenile idiopathic arthritis with mass cytometry. 61
30089725 2018
22
Brief Report: The Genetic Profile of Rheumatoid Factor-Positive Polyarticular Juvenile Idiopathic Arthritis Resembles That of Adult Rheumatoid Arthritis. 61
29426059 2018
23
Plasma exchange successfully treated macrophage activation syndrome in rheumatoid factor-positive polyarticular juvenile idiopathic arthritis with co-existing pneumonia. 61
28328098 2018
24
Bilateral absence of the cruciate ligaments with meniscal dysplasia: Unexpected diagnosis in a child with juvenile idiopathic arthritis. 61
29635139 2018
25
High Levels of DEK Autoantibodies in Sera of Patients With Polyarticular Juvenile Idiopathic Arthritis and With Early Disease Flares Following Cessation of Anti-Tumor Necrosis Factor Therapy. 61
29287303 2018
26
Switched Memory B Cells Are Increased in Oligoarticular and Polyarticular Juvenile Idiopathic Arthritis and Their Change Over Time Is Related to Response to Tumor Necrosis Factor Inhibitors. 61
29316374 2018
27
Adiposity in Juvenile Psoriatic Arthritis. 61
29247150 2018
28
Is palindromic rheumatism amongst children a benign disease? 61
29439723 2018
29
The First Report of Multicentric Carpotarsal Osteolysis Syndrome Caused by MAFB Mutation in Asian. 61
30305815 2018
30
Prior to extension, Transcriptomes of fibroblast-like Synoviocytes from extended and Polyarticular juvenile idiopathic arthritis are indistinguishable. 61
29310668 2018
31
Protocols on classification, monitoring and therapy in children's rheumatology (PRO-KIND): results of the working group Polyarticular juvenile idiopathic arthritis. 61
29116003 2017
32
Tocilizumab (Actemra). 61
28841363 2017
33
Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents. 61
28770976 2017
34
Interleukin-33 as a marker of disease activity in rheumatoid factor positive polyarticular juvenile idiopathic arthritis. 61
27785924 2017
35
Spontaneous regression of Epstein-Barr virus-associated lymphoproliferative disorder in a juvenile idiopathic arthritis patient after the discontinuation of methotrexate and etanercept. 61
28638688 2017
36
Golimumab: A Review in Inflammatory Arthritis. 61
28530020 2017
37
Juvenile Idiopathic Arthritis. 61
28418334 2017
38
Safety of tocilizumab in the treatment of juvenile idiopathic arthritis. 61
28277841 2017
39
No association between vitamin D levels around time of birth and later risk of developing oligo- and polyarticular juvenile idiopathic arthritis: a Danish case-cohort study. 61
27460412 2017
40
Monitoring of Epstein-Barr virus load and killer T cells in patients with juvenile idiopathic arthritis treated with methotrexate or tocilizumab. 61
27166661 2017
41
Pathway analysis based on Monte Carlo Cross-Validation in polyarticular juvenile idiopathic arthritis. 61
27894617 2017
42
Predictors of methotrexate response in Turkish children with oligoarticular and polyarticular juvenile idiopathic arthritis. 61
29168357 2017
43
Cost-Effectiveness Analysis of First-Line Treatment With Biologic Agents in Polyarticular Juvenile Idiopathic Arthritis. 61
27059807 2016
44
Biological agents in polyarticular juvenile idiopathic arthritis: A meta-analysis of randomized withdrawal trials. 61
27989499 2016
45
Safety and efficacy of etanercept and adalimumab in children aged 2 to 4 years with juvenile idiopathic arthritis. 61
27709443 2016
46
A Novel Method for Pathway Identification Based on Attractor and Crosstalk in Polyarticular Juvenile Idiopathic Arthritis. 61
27804927 2016
47
Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab. 61
27881144 2016
48
Multifocal pigmented villonodular synovitis in a child: A case report. 61
27537585 2016
49
Whole blood expression profiling from the TREAT trial: insights for the pathogenesis of polyarticular juvenile idiopathic arthritis. 61
27388672 2016
50
Prediction of long-term remission of oligo/polyarticular juvenile idiopathic arthritis with S100A12 and vascular endothelial growth factor. 61
26474088 2016

Variations for Polyarticular Juvenile Idiopathic Arthritis

Expression for Polyarticular Juvenile Idiopathic Arthritis

Search GEO for disease gene expression data for Polyarticular Juvenile Idiopathic Arthritis.

Pathways for Polyarticular Juvenile Idiopathic Arthritis

Pathways related to Polyarticular Juvenile Idiopathic Arthritis according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.81 TNF IFNG HLA-DRB4 BTK
2
Show member pathways
12.22 TNF IFNG HLA-DRB4
3 12.17 TNF IFNG BTK
4
Show member pathways
12.16 TNF IFNG HLA-DRB4 BTK
5
Show member pathways
11.82 TNF IFNG HLA-DRB4
6 11.75 TNF IFNG HLA-DRB4
7 11.54 TNF IFNG BTK
8
Show member pathways
11.48 TNF IFNG HLA-DRB4 BTK
9 11.47 TNF BTK
10 11.46 TNF IFNG
11
Show member pathways
11.4 TNF IFNG
12
Show member pathways
11.38 TNF IFNG
13 11.35 TNF IFNG
14 11.28 TNF IFNG
15 11.27 TNF IFNG
16
Show member pathways
11.26 TNF IFNG
17 11.23 TNF IFNG
18 11.22 TNF IFNG
19 11.15 TNF IFNG
20 11.1 TNF IFNG HLA-DRB4
21 11.02 TNF IFNG
22 10.94 TNF IFNG
23 10.87 TNF IFNG

GO Terms for Polyarticular Juvenile Idiopathic Arthritis

Biological processes related to Polyarticular Juvenile Idiopathic Arthritis according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 adaptive immune response GO:0002250 9.7 IFNG HLA-DRB4 BTK
2 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.61 TNF IFNG
3 interferon-gamma-mediated signaling pathway GO:0060333 9.6 IFNG HLA-DRB4
4 regulation of insulin secretion GO:0050796 9.59 TNF IFNG
5 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.58 TNF BTK
6 apoptotic signaling pathway GO:0097190 9.58 TNF BTK
7 humoral immune response GO:0006959 9.57 TNF IFNG
8 positive regulation of protein localization to plasma membrane GO:1903078 9.56 TNF IFNG
9 positive regulation of phagocytosis GO:0050766 9.55 TNF IFNG
10 extrinsic apoptotic signaling pathway GO:0097191 9.54 TNF IFNG
11 positive regulation of nitric oxide biosynthetic process GO:0045429 9.51 TNF IFNG
12 positive regulation of protein complex assembly GO:0031334 9.49 TNF IFNG
13 microglial cell activation GO:0001774 9.48 TNF IFNG
14 positive regulation of osteoclast differentiation GO:0045672 9.46 TNF IFNG
15 positive regulation of amyloid-beta formation GO:1902004 9.43 TNF IFNG
16 astrocyte activation GO:0048143 9.4 TNF IFNG
17 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.37 TNF IFNG
18 positive regulation of chemokine biosynthetic process GO:0045080 9.32 TNF IFNG
19 negative regulation of amyloid-beta clearance GO:1900222 9.26 TNF IFNG
20 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.16 TNF IFNG
21 positive regulation of vitamin D biosynthetic process GO:0060557 8.96 TNF IFNG
22 positive regulation of nitrogen compound metabolic process GO:0051173 8.62 TNF IFNG

Sources for Polyarticular Juvenile Idiopathic Arthritis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....